Cooperation SeekingCreative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Olaratumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
PDGFR signaling is a tyrosine kinase-mediated pathway that normally regulates cell growth, chemotaxis, and mesenchymal stem cell differentiation. Olaratumab is a fully human IgG1 monoclonal antibody with antitumor activity and can selectively bind to the outer domain of human platelet-derived growth factor receptor (PDGFR) -α with high affinity. Olaratumab blocks ligand-induced tumor cell proliferation and inhibits receptor autophosphorylation and ligand-induced phosphorylation of downstream signaling molecules protein kinase B (Akt) and mitogen-activated protein kinase 5.
Olaratumab in combination with adriamycin for the treatment of adult patients with advanced or metastatic soft tissue sarcoma (STS) of histological subtype
All products and services are for Research Use Only. Do Not use in humans.
Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.